















A**B****MGMT probes****C****EReg signature****D****G-CIMP-low progression Risk****E****Stemness Index****Legends for the heatmaps:**



A**B****C****D****E**

A**B****C**


IDH mut probes (N=114)
IDH-related tumors






IDH wt probes (N=124)
IDH-related tumors

**E****D**

IDH mut probes (N=114)
TCGA PanCancer



IDH wt probes (N=124)
TCGA PanCancer


**F****G**

A**Longitudinal Glioma-eLB Score (By Patient)**

33 Pairs, 71 Samples

Classification ■ Primary ● 1st Recurrent ▲ 2nd/3rd Recurrent ◆ Follow-up

Glioma-eLB Score (GeLB: %)

**B**